2 active not recruiting, 2 recruiting, 2 terminated, 2 withdrawn. 6 Phase 2, 3 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 2, Terminated 2, Completed 1, Withdrawn 1 |
| Phase 1 | 3 | Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Early Phase 1 | 1 | Active not recruiting 1 |
Follow IDH2 Gene Mutation: new trials by email Literature Review of IDH2 Gene Mutation trials Research Report on IDH2 Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Niraparib In Recurrent IDH 1/2 Gliomas Niraparib, Resection/Treatment with Niraparib - Low-grade Glioma, IDH2 Gene Mutation | Early Phase 1 | Active not recruiting | Massachusetts General Hospital | 16 | 2023-05-18 | 2026-07-24 |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms Ivosidenib, Enasidenib, Fedratinib - IDH Mutation, IDH1 Mutation | Phase 1 | Withdrawn | University of Chicago | 2021-10-29 | 2024-07-31 | |
| Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Enasidenib, Venetoclax - Acute Myeloid Leukemia, Relapsed Cancer | Phase 1 / Phase 2 | Terminated | University Health Network, Toronto | 27 | 2020-11-05 | 2024-01-24 |
| IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT Enasidenib - Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 2 | Completed | Heinrich-Heine University, Duesseldorf | 50 | 2020-08-27 | 2024-09-19 |
| Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation Enasidenib, Hematopoietic Cell Transplantation - Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2019-12-02 | 2021-03-10 | |
| BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas PARP Inhibitor BGB-290, Temozolomide (TMZ) - Glioblastoma, IDH1 Gene Mutation | Phase 1 | Active not recruiting | University of California, San Francisco | 78 | 2019-04-03 | 2026-03-13 |
| Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Azacitidine, Enasidenib Mesylate - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2018-09-18 | 2026-09-14 |
| Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis Busulfan, Cyclophosphamide, Fludarabine - Anemia, ASXL1 Gene Mutation | Phase 2 | Terminated | University of Utah | 6 | 2018-03-30 | 2022-05-05 |
| Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome Azacitidine, Enasidenib, Quality-of-Life Assessment - Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 63 | 2018-01-17 | 2026-09-04 |
| Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia Acute Myeloid Leukemia, IDH1 Gene Mutation | Unknown | Istituto Clinico Humanitas | 654 | 2016-01-01 | 2020-05-13 |
Leukemia, Myeloid, Acute (6) · Leukemia, Myelomonocytic, Chronic (3) · Glioma (2) · Myelodysplastic Syndromes (2) · Anemia (1) · Anemia, Refractory, with Excess of Blasts (1) · Glioblastoma (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Multiple Myeloma (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Primary Myelofibrosis (1) · Recurrence (1)
Neoplasms by Histologic Type (10) · Neoplasms (9) · Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Leukemia (6) · Leukemia, Myeloid (6) · Bone Marrow Diseases (5) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Chronic Disease (3) · Myelodysplastic-Myeloproliferative Diseases (3) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphoproliferative Disorders (2)
enasidenib (6) · Azacitidine (2) · Hematopoietic Stem Cell Transplantation (2) · Stem Cell Transplantation (2) · 2-Propanol (1) · Busulfan (1) · Cyclophosphamide (1) · Temozolomide (1) · Therapeutics (1) · fedratinib (1) · fludarabine (1) · ivosidenib (1) · methanesulfonic acid (1) · niraparib (1) · pamiparib (1)
M.D. Anderson Cancer Center (2) · Heinrich-Heine University, Duesseldorf (1) · Istituto Clinico Humanitas (1) · Massachusetts General Hospital (1) · Roswell Park Cancer Institute (1) · University Health Network, Toronto (1) · University of California, San Francisco (1) · University of Chicago (1) · University of Utah (1)
United States (7) · Canada (1) · Germany (1) · Italy (1)
Courtney DiNardo (2) · Catherine Lee, MD (1) · Christoph Roellig (1) · Elizabeth Griffiths, MD (1) · Francesc Sole, MD (1) · Isabel Arrillaga-Romany, MD, Phd (1) · Joana Desterro (1) · Jorge Sierra (1) · Klaus Metzeler (1) · Lisa Pleyer (1) · Maria Teresa Voso (1) · Matteo Della Porta, MD (1) · Moritz Middeke (1) · Olatoyosi Odenike, MD (1) · Pau Montesinos (1)
PMID 20142433, PMID 20171147, PMID 20421455, PMID 21079611, PMID 21130701, PMID 22453240, PMID 23393090, PMID 23558173, PMID 23634996, PMID 23641016, PMID 23645565, PMID 24030381, PMID 24935723, PMID 26016821, PMID 35078972, PMID 35973199, PMID 41075807
2019 (1), P30CA016672 (1)